Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
- Conditions
- Interventions
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Yvan Beaussant, MD, MSci
- Target Recruit Count
- 15
- Registration Number
- NCT04950608
- Locations
- 🇺🇸
Care Dimensions, Danvers, Massachusetts, United States
Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
- Conditions
- Interventions
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Beckley Psytech Limited
- Target Recruit Count
- 4
- Registration Number
- NCT04905121
- Locations
- 🇬🇧
King's College London, London, United Kingdom
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04754061
- Locations
- 🇨🇦
Bruyere Continuing Care, Ottawa, Ontario, Canada
🇨🇦The Ottawa Hospital, Ottawa, Ontario, Canada
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 19
- Registration Number
- NCT04739865
- Locations
- 🇮🇪
Sheaf House, Tallaght Hospital, Dublin, Ireland
🇺🇸Kadima Neuropsychiatry Institute, La Jolla, California, United States
Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Anders Fink-Jensen, MD, DMSci
- Target Recruit Count
- 10
- Registration Number
- NCT04718792
- Locations
- 🇩🇰
Psychiatric Center Copenhagen, Copenhagen, Frederiksberg, Denmark
Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression
- Conditions
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 144
- Registration Number
- NCT04670081
- Locations
- 🇩🇪
Central Institute of Mental Health (CIMH), Mannheim, Germany
🇩🇪Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy, Berlin, Germany
Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 16
- Registration Number
- NCT04661514
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute, La Jolla, California, United States
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04656301
- Locations
- 🇺🇸
New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, United States
The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-04-19
- Target Recruit Count
- 35
- Registration Number
- NCT04630964
- Locations
- 🇸🇪
Northern Stockholm Spychiatry Clinic, Stockholm, Sweden
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 90
- Registration Number
- NCT04620759
- Locations
- 🇺🇸
Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.